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Abstract: 
The composition and activity of the gut microbiota codevelop with the host from birth and is 
subject to a complex interplay that depends on the host genome, nutrition, and life-style. The gut 
microbiota is involved in the regulation of multiple host metabolic pathways, giving rise to 
interactive host-microbiota metabolic, signaling, and immune-inflammatory axes that 
physiologically connect the gut, liver, muscle, and brain. A deeper understanding of these axes is 
a prerequisite for optimizing therapeutic strategies to manipulate the gut microbiota to combat 
disease and improve health.  
 
Article: 
Coelomate animals possess an internal body cavity surrounding the gut and other organs and 
have coevolved with a diverse range of symbiotic gut bacteria and other microorganisms 
collectively known as the gut microbiota [see Perspective by Gordon (1)]. This mutually 
beneficial relationship between the host and its resident microbiota results in production of 
metabolites by microbes that contribute to the evolutionary fitness of the host (2). The diversity 
and composition of the gut microbiota within and between individuals of a host species is 
influenced by topographical and temporal variation in the microbial communities, with particular 
bacterial species occupying specific niches in the body habitat or being associated with particular 
growth or maturation phases of the host (1, 3). In humans, the primary individual microbiota may 
reflect the maternal hand-over of “seed ecology” species at birth (4, 5). Subsequent shaping of 
the microbial landscape is then driven by a series of complex and dynamic interactions 
throughout life, including diet, life-style, disease, and antibiotic use. This developmental 
trajectory of the microbiome, incorporating the microbes and their collective genomes, 
modulates the metabolic phenotype of the host and greatly influences host biochemistry and 
susceptibility to disease (6).  
 
Interactions between the gut microbiota and the host immune system begin at birth. The 
microbiota shapes the development of the immune system, and the immune system in turn 
shapes the composition of the microbiota. This cross-talk between the microbes and the host 
immune system is transmitted through a vast array of signaling pathways that involve many 
different classes of molecules and extend beyond the immune system. These immune-mediated 
signaling processes, together with direct chemical interactions between the microbe and host, act 
upon multiple organs such as the gut, liver, muscle, and brain. Together these complex 
interactions comprise a series of host-microbe metabolic axes. We define a host-microbe 
metabolic axis as a multidirectional interactive chemical communication highway between 
specific host cellular pathways and a series of microbial species, subecologies, and activities. 
Within these metabolic axes, multiple bacterial genomes can sequentially modulate metabolic 
reactions, resulting in combinatorial metabolism of substrates by the microbiome and host 
genome, exemplified by production of bile acids, choline, and short-chain fatty acids (SCFAs) 
that are essential for host health (6). In addition, the production of these metabolites by microbes 
contributes to the host metabolic phenotype and hence to disease risk. The profound influence of 
the gut microbiota on the host immune system is strongly associated with long-term health 
prospects [see Review by Hooper et al. in this issue (7) and Review by Blumberg and Powrie 
(8)]. The composition of the core gut microbiota is considered to be essentially stable throughout 
adulthood. However, there are components that are dynamic and biologically and metabolically 
flexible, responding to perturbations such as environmental stresses or changes in diet by 
alteration in species composition that may influence health or disease risk (9).  
 
The increased incidence of gut dysbiosis (an imbalance in the intestinal bacteria leading to 
disease) in western populations over the past 60 years is associated with a variety of factors, 
ranging from the now-textbook story of gastric ulcers caused by infection with the bacterium 
Helicobacter pylori to life-style-related diseases such as diabetes and obesity. Hence, there is 
much interest in developing new therapeutic tools for manipulating the composition of the gut 
microbiota to benefit host health. A better understanding of how variations in the symbiotic 
supraorganism contribute to disease risk and health sustainability will point the way to new 
therapeutic interventions and disease prevention strategies [see Review by Holmes et al. (10)].  
 
THE MICROBIAL AGES OF MAN 
The microbiota of the infant is seeded at birth and is initially undifferentiated across the various 
body habitats. A variety of factors—including method of delivery (vaginal versus Cesarian 
section), breast feeding, and weaning—influence the infant microbiota (Fig. 1). For example, the 
microbiota of babies delivered vaginally are dominated by Lactobacillus, Prevotella, and 
Atopobium, whereas babies delivered by Cesarian section have a microbiota that more closely 
resembles that of the maternal skin community, with staphylococci being a dominant early 
member (4). Evidence is beginning to emerge that the in utero environment may not be sterile as 
originally thought, with bacteria such as Enterococcus fecalis, Staphylococcus epidermidis, and 
Escherichia coli having been isolated from the meconium (earliest feces) of healthy neonates 
(11). The dominance of aerobic bacteria at birth is altered during peri- and postnatal 
development. The microbiota diversifies over the first few weeks of life to form a complex 
anaerobe-dominated microbial community (12). This early colonization period coincides with 
activation of the hypothalamic-pituitary-adrenal (HPA) axis, which has an impact on the enteric 
nervous system that innervates the gastrointestinal (GI) tract. Enteroendocrine cells of the gut 
secrete a variety of metabolically related peptides all known to be connected to food intake, lipid 
storage, and energy homeostasis and can be activated by microbial metabolites, such as SCFAs, 
that act through heterotrimeric guanine nucleotide–binding protein (G protein)–coupled 
receptors, such as the GPR41 receptor expressed by enteroendocrine cells (13). The gut 
microbiota appears to become more stable throughout adulthood, although some studies have 
reported that adolescents have a higher abundance of bifidobacteria and clostridia than adults 
(14). A final set of age-related shifts in the composition and function of the gut microbiota 
occurs during old age. Aging is associated with altered physiological functions, including 
immune system function, that affect gut microbiota composition. Age-related differences 
reported in gut microbiota composition include an increase in the total number of facultative 
anaerobes, shifts in the ratio of Bacteroidetes to Firmicutes species, and a marked decrease in 
bifidobacteria in people >60 years old, around the time that the immune system starts to decline 
(Fig. 1) (15). Metabolic changes coinciding with the evolution and maturation of the gut 
microbiota can be found in the excretion profiles of bacterial products of amino acid metabolism 
and in energy-related metabolites. For example, bacterial products of choline metabolism may be 
inversely associated with age in children under 12 years old (16). Changes in the urinary 
excretion of 4-hydroxyphenylacetic acid, indoleacetic acid, and tricarboxylic acid cycle 
metabolites have been found during early-onset puberty (17). Integration of age-specific urinary 
or fecal profiles with bacterial genome sequencing data should provide new insights into the 
functional coevolution of the microbiota and host.  
 
 
 
Figure 1: The gut microbiota in development and disease. The influence of the gut microbiota on human health is 
continuous from birth to old age. The maternal microbiota may influence both the intrauterine environment and the 
postnatal health of the fetus. At birth, about 100 microbial species populate the colon. Early environmental factors 
(e.g., method of delivery), nutritional factors (e.g., breast or bottle-feeding), and epigenetic factors have been 
implicated in the development of a healthy gut and its microbial symbionts. Changes in gut microbial composition in 
early life can influence risk for developing disease later in life. During suckling, the microbial community develops 
rapidly; shifts in microbial diversity occur throughout childhood and adult life; and in old age, there is a decrease in 
the Bacteroidetes and an increase in Firmicutes species. The gut microbiota is important for maintaining normal 
physiology and energy production throughout life. Body temperature regulation, reproduction, and tissue growth are 
energy-dependent processes that may rely in part on gut microbial energy production. Extrinsic environmental 
factors (such as antibiotic use, diet, stress, disease, and injury) and the mammalian host genome continually 
influence the diversity and function of the gut microbiota with implications for human health. Disruption of the gut 
microbiota (dysbiosis) can lead to a variety of different diseases, including (A) inflammatory bowel disease, colon 
cancer, and irritable bowel syndrome; (B) gastric ulcers, nonalcoholic fatty liver disease, and obesity and metabolic 
syndromes; (C) asthma, atopy, and hypertension; and (D) mood and behavior through hormone signaling (e.g., GLP-
1). The gut microbiota is also important for drug metabolism and preventing the establishment of pathogenic 
microbes.  
 
 
HOST AND MICROBIOTA COMETABOLISM AND SIGNALING 
The host and its gut microbiota coproduce a large array of small molecules during the 
metabolism of food and xenobiotics (compounds of nonhost origin that enter the gut with the diet 
or are produced by the microbiota), many of which play critical roles in shuttling information 
between host cells and the host’s microbial symbionts. Different regions of the human GI tract 
vary in terms of the composition of indigenous microbiota (1, 4). For each compartment of the 
GI tract, a chemical dialogue exists among different microbial species (direct substrate provision 
in the microbial food web, quorum sensing, contact-dependent signaling, and potentially 
gasotransmitters) (18) as well as between microbial symbionts and host cells (3, 19). This 
chemical dialogue includes signaling via low molecular weight metabolites, peptides, and 
proteins or may take place indirectly through immune-mediated pathways. Some of the main 
chemical classes that regulate host-microbiota interactions are described in Table 1, but it is 
likely that many more exist.  
 
Humans excrete between 50 to 100 mg of volatile phenols per day, predominantly in the form of 
4-cresol and phenol (mainly as glucuronide and sulfate conjugates) with lower amounts of 4-
ethylphenol (20). The production of cresols from tyrosine in mammals has been attributed to 
various species of Clostridium, Bifidobacterium, and Bacteroides fragilis. Other bacteria such as 
E. coli are associated with phenol production. Altered levels of 4-cresol metabolites in human 
urine have been associated with diverse physiological and pathological conditions from weight 
loss to inflammatory bowel disease. These conditions are also associated with altered microbiota 
composition, namely a reduction in the diversity of the microbiota because of loss of 
Lactobacillus and Bacteroides species in the case of inflammatory bowel disease (21) and 
differences in the ratio of the Firmicutes to Bacteroidetes species in the case of weight loss (22).  
 
Dietary fiber (complex carbohydrates) can be digested and subsequently fermented in the colon 
by gut microbes into SCFAs such as n-butyrate, acetate, and propionate and are sensed by the G 
protein–coupled receptors, GPR41 and GPR43, expressed by gut enteroendocrine cells (13). In 
addition to being a local nutrient source for colonocytes and a minor nutrient source for microbes 
such as Desulfotomaculum spp. in the GI tract (23), n-butyrate has also been shown in cell-
culture models and mice to regulate energy homeostasis by stimulating leptin production in 
adipocytes, as well as inducing glucagon-like peptide-1 (GLP-1) secretion by the intestinal 
enteroendocrine L cells (13). The main producers of butyrate are clostridia, eubacteria, and 
roseburia microbes. n-Butyrate regulates neutrophil function and migration, inhibits 
inflammatory cytokine-induced expression of vascular cell adhesion molecule-1, increases 
expression of tight junction proteins in colon epithelia, and exhibits anti-inflammatory effects 
 
Table 1: Gut bacteria and the metabolites they contribute.  
Metabolites Related bacteria Potential biological functions References 
Short-chain fatty acids: acetate, propionate, butyrate, 
isobutyrate, 2-methylpropionate, valerate, isovalerate, 
hexanoate 
Clostridial clusters IV and 
XIVa of Firmicutes, 
including species of 
Eubacterium, Roseburia, 
Faecalibacterium, and 
Coprococcus 
Decreased colonic pH, inhibit the 
growth of pathogens; stimulate water 
and sodium absorption; participate in 
cholesterol synthesis; provide energy to 
the colonic epithelial cells, implicated 
in human obesity, insulin resistance and 
type 2 diabetes, colorectal cancer.  
(13, 24, 57)  
Bile acids: cholate, hyocholate, deoxycholate, 
chenodeoxycholate, α-muricholate, β-muricholate, ω-
muricholate, taurocholate, glycocholate, 
taurochenoxycholate, glycochenodeoxycholate, 
taurocholate, tauro-α-muricholate, tauro-β-
muricholate, lithocholate, ursodeoxycholate, 
hyodeoxycholate, glycodeoxylcholate, 
taurohyocholate, taurodeoxylcholate  
Lactobacillus, 
Bifidobacteria, 
Enterobacter, Bacteroides, 
Clostridium 
Absorb dietary fats and lipid-soluble 
vitamins, facilitate lipid absorption, 
maintain intestinal barrier function, 
signal systemic endocrine functions to 
regulate triglycerides, cholesterol, 
glucose and energy homeostasis.  
(30, 31, 33)  
Choline metabolites: methylamine, dimethylamine, 
trimethylamine, trimethylamine-N-oxide, 
dimethylglycine, betaine  
Faecalibacterium 
prausnitzii, 
Bifidobacterium 
Modulate lipid metabolism and glucose 
homeostasis. 
Involved in nonalcoholic fatty liver 
disease, dietary induced obesity, 
diabetes, and cardiovascular disease.  
(29, 58)  
Phenolic, benzoyl, and phenyl derivatives: benzoic 
acid, hippuric acid, 2-hydroxyhippuric acid, 2-
hydroxybenzoic acid, 3-hydroxyhippuric acid, 3-
hydroxybenzoic acid, 4-hydroxybenzoic acid, 3-
hydroxyphenylpropionate, 4-
hydroxyphenylpropionate, 3-hydroxycinnamate, 4-
methylphenol, tyrosine, phenylalanine, 4-cresol, 4-
cresyl sulfate, 4-cresyl glucuronide, 4-
hydroxyphenylacetate, 3,4-dihydroxyphenylacetate, 
phenylacetylglycine, phenylacetylglutamine, 
phenylacetylglycine, phenylacetate, 
phenylpropionate, phenylpropionylglycine, 
cinnamoylglycine  
Clostridium difficile, F. 
prausnitzii, 
Bifidobacterium, 
Subdoligranulum, 
Lactobacillus 
Detoxification of xenobiotics; indicate 
gut microbial composition and activity; 
utilize polyphenols. 
Urinary hippuric acid may be a 
biomarker of hypertension and obesity 
in humans. Urinary 4-
hydroxyphenylacetate, 4-cresol, and 
phenylacetate are elevated in colorectal 
cancer. Urinary 4-cresyl sulfate is 
elevated in children with severe autism.  
(59, 60)  
Indole derivatives: N-acetyltryptophan, indoleacetate, 
indoleacetylglycine (IAG), indole, indoxyl sulfate, 
indole-3-propionate, melatonin, melatonin 6-sulfate, 
serotonin, 5-hydroxyindole  
Clostridium sporogenes, 
E. coli 
Protect against stress-induced lesions in 
the GI tract; modulate expression of 
proinflammatory genes, increase 
expression of anti-inflammatory genes, 
strengthen epithelial cell barrier 
properties. Implicated in GI 
pathologies, brain-gut axis, and a few 
neurological conditions.  
(61–63)  
Vitamins: vitamin K, vitamin B12, biotin, folate, 
thiamine, riboflavin, pyridoxine 
Bifidobacterium Provide complementary endogenous 
sources of vitamins, strengthen immune 
function, exert epigenetic effects to 
regulate cell proliferation.  
(64, 65)  
Polyamines: putrescine, cadaverine, spermidine, 
spermine 
Campylobacter jejuni, 
Clostridium 
saccharolyticum 
Exert genotoxic effects on the host, 
anti-inflammatory and antitumoral 
effects. Potential tumor markers. 
(66, 67)  
Lipids: conjugated fatty acids, LPS, peptidoglycan, 
acylglycerols, sphingomyelin, cholesterol, 
phosphatidylcholines, phosphoethanolamines, 
triglycerides  
Bifidobacterium, 
Roseburia, Lactobacillus, 
Klebsiella, Enterobacter, 
Citrobacter, Clostridium 
Impact intestinal permeability, activate 
intestine-brain-liver neural axis to 
regulate glucose homeostasis; LPS 
induces chronic systemic inflammation; 
conjugated fatty acids improve 
hyperinsulinemia, enhance the immune 
system and alter lipoprotein profiles. 
Cholesterol is the basis for sterol and 
bile acid production.  
(42, 68)  
Others: D-lactate, formate, methanol, ethanol, 
succinate, lysine, glucose, urea, α-ketoisovalerate, 
creatine, creatinine, endocannabinoids, 2-
arachidonoylglycerol (2-AG), N-
arachidonoylethanolamide, LPS, etc.  
Bacteroides, 
Pseudobutyrivibrio, 
Ruminococcus, 
Faecalibacterium, 
Subdoligranulum, 
Bifidobacterium, 
Atopobium, Firmicutes, 
Lactobacillus 
Direct or indirect synthesis or 
utilization of compounds or modulation 
of linked pathways including 
endocannabinoid system. 
(43, 60, 69)  
by reducing cytokine and chemokine release from human immune cells. Therefore, n-butyrate or 
specific species of butyrate-producing gut bacteria may be a new target for restoring host 
immune function and barrier integrity and for regulating energy metabolism. n-Butyrate can also 
be directly used by colon epithelial cells to produce ketone bodies and carbon dioxide. Other 
SCFAs such as propionate and acetate are carried in the bloodstream to a variety of different 
organs, where they are used as substrates for oxidation, lipid synthesis, and energy metabolism, 
particularly by the hepatocyte cells of the liver, which use propionate for gluconeogenesis (13, 
24). SCFAs have been reported to regulate the function of histone deacetylases (HDACs), 
stimulate the sympathetic nervous system, and may influence social behavior in rodents (25). 
SCFAs have also been shown to stimulate gut motility and intestinal transit and at physiological 
concentrations have been shown to induce an eight- to 10-fold increase in serotonin release in an 
in vitro colonic mucosal system (26). SCFAs are clearly one of the most important gut microbial 
products and affect a range of host processes—including energy utilization, host-microbe 
signaling, and control of colonic pH—with consequent effects on microbiota composition, gut 
motility, and epithelial cell proliferation (27).  
 
Choline is an essential dietary nutrient and is primarily metabolized in the liver. However, gut 
microbial enzymes also catalyze the conversion of dietary choline to trimethylamine (28), which 
is then further metabolized by the flavine monooxygenase system in the liver to produce 
trimethylamine-N-oxide. The microbial conversion of dietary choline is emerging as a metabolic 
hallmark that is associated with liver and cardiovascular diseases. For example, 129S6 mice are 
known to be susceptible to developing obesity, impaired glucose tolerance, and nonalcoholic 
fatty liver disease. When they are fed a high-fat diet, there is an increase in microbial enzyme 
activity that leads to reduced choline bioavailability, resulting in symptoms that mimic 
nonalcoholic fatty liver disease; these symptoms are also seen in mice fed a choline-deficient diet 
(28). A study by Wang et al. (29) recently suggested a potential pathological role for 
trimethylamine-N-oxide in the development of atherosclerosis, providing a potential link 
between the intestinal microbiota, dietary choline, and cardiovascular disease risk.  
 
Bile acids (or bile salts) are steroid acids that are produced in the liver from cholesterol and 
secreted in bile and whose main function is to facilitate the metabolism of dietary fat and the 
absorption of fat-soluble vitamins and cholesterol. They complete an enterohepatic cycle 
between the gut and liver about eight times per day, with 90 to 95% of bile acids being 
reabsorbed by the intestine and returned to the liver, whereupon they are conjugated 
predominantly with taurine and glycine to form bile salts. About 5 to 10% of bile acids are 
biotransformed largely through degradation by intestinal bacteria and some are lost in the feces. 
The transformation of bile acids in the intestines is mainly performed by anaerobic bacteria of 
the genera Bacteroides, Eubacterium, and Clostridium and involves deconjugation of taurine- 
and glycine-conjugated bile acids through the action of bile salt hydrolases to their respective 
unconjugated free bile acids. These free bile acids then form secondary bile acids such as 
deoxycholate and lithocholate (30, 31), which in turn undergo reabsorption, mainly by bile acid 
transporters in the ileal epithelium but also by passive absorption throughout the intestine (32). 
Bile salt hydrolase enzymes have been identified in several bacterial species, mainly anaerobes 
of the genera Bacteroides, Clostridium, Eubacterium, Lactobacillus, and Escherichia. 
Deconjugation and 7αβ-dehydroxylation of bile salts increases their hydrophobicity and hence 
absorption, which has also been associated with increased pathological effects (30). A minor 
portion of bile acid biotransformation may also be conducted by various groups of aerobic 
bacteria, such as actinobacteria and proteobacteria. As further evidence for the importance of the 
microbiota in bile salt metabolism, a study has shown that rodents raised under germ-free 
conditions or treated with antibiotics have altered hepatic gene expression patterns with changes 
in genes associated with cholesterol, steroid, and bile acid synthesis as well as altered conjugated 
(especially taurine-conjugated) bile acid signatures in multiple body compartments (33). Bile 
acid metabolites formed by the interaction of both mammalian and gut microbial metabolisms 
(cometabolites) are major ligands for nuclear hormone receptors and strongly activate an 
important member of this family, the farnesoid X receptor. Farnesoid X receptor signaling 
affects many target genes, including those involved in bile acid synthesis and transport and lipid 
and carbohydrate metabolism, and is involved in the regulation of intestinal innate immunity 
(34). The gut microbiota could, through effects on bile acid metabolism in the gut lumen, 
influence signaling pathways involved in energy and lipid metabolism, leading to alterations in 
lipid peroxidation, production of hepatic fatty acids, and triglyceride storage. High 
concentrations of secondary bile acids in various biological fluids have been associated with 
diseases such as colon cancer (30). Interestingly, it has been demonstrated that bile salt hydrolase 
activity is a feature of all major bacterial groups, and modulation of bile salt hydrolase activity 
may be an effective target in the management of obesity and metabolic syndrome (35).  
 
LIVER FUNCTION AND INFLAMMATION IN METABOLIC DISEASE 
Over the past 50 years, the prevalence of metabolic diseases such as diabetes and obesity has 
steadily increased in the developed world (36), the principal culprits being originally attributed to 
poor diet and lack of exercise. Events early in life, such as delivery mode, maternal pre-
pregnancy body mass index, and antibiotic treatment during infancy, influence obesity in later 
childhood (37). Studies in monozygotic and dizygotic twin pairs concordant for leanness or 
obesity and their mothers showed that the human gut microbiome is shared among family 
members with a comparable degree of covariation in gut microbiota species between the twin 
pairs (38). In seminal work, Gordon and his colleagues demonstrated that the intestinal 
microbiota can cause metabolic disease in mice independently of genetic background (39, 40). 
Briefly, the colonization of a germ-free mouse with the intestinal microbiota from an obese 
mouse donor induced a body weight gain that was more substantial than when the microbiota 
from a lean mouse was transferred (41). This study provided the first insight into the potential 
contribution of the microbiota to the obesity epidemic. The same group also observed that the 
intestinal microbiota of obese individuals differed in microbial diversity compared with that of 
lean persons, with a lower prevalence of Bacteroidetes and a higher prevalence of Firmicutes 
(39). Because of differences in the composition of their gut microbiota, obese persons may be 
more effective at extracting energy from food and stimulating lipogenesis (41). An increase in 
lipopolysaccharide (LPS), a component of the outer membranes of Gram-negative bacteria, 
generates low-grade chronic inflammation (metabolic endotoxemia) in mice, resulting in insulin 
resistance (42) that may act through endocannabinoids produced by the host (43). Prebiotics are 
nondigestible food substrates that promote the growth of intestinal bacteria that confer health 
benefits on the host. It has been shown that a high-fat diet increases the proportion of Gram-
negative to Gram-positive microbes in the gut by favoring their growth and hence increases the 
liberation of LPS, which is responsible for inflammation (42). Importantly, this effect can be 
suppressed with a prebiotic that specifically boosts growth of Gram-positive microbes (44). 
From this transplantable “second genome,” another causal mechanism for metabolic disease has 
been characterized, namely increased capacity of the gut microbiota from obese mice to harvest 
energy for the host. The transplanted microbiota from obese mice promoted absorption of 
monosaccharides from the gut lumen, selectively suppressed the production of fasting-induced 
adipocyte factor (Fiaf), a circulating lipoprotein lipase inhibitor, with resulting induction of de 
novo hepatic lipogenesis and deposition of triglycerides in adipocytes and the liver (40). 
Nontransplanted germ-free lean mice were resistant to becoming obese on a fat-enriched diet, 
with an increase in skeletal muscle and liver of phosphorylated adenosine monophosphate–
activated protein kinase (AMPK). AMPK phosphorylates acetyl coenzyme A (CoA) carboxylase, 
which results in decreased malonylCoA levels. Given that malonylCoA controls the rate-limiting 
step of long-chain fatty acylCoA entry to the mitochondria by blocking the enzyme carnitine-
palmitoyltransferase, fatty acid oxidation is promoted, which is associated with lower storage of 
fat (40, 45). The contribution of bacterial LPS to metabolic syndrome and other inflammatory 
conditions is indisputable, and the use of peptides with antimicrobial properties to achieve 
immunomodulation by sequestering LPS is an attractive therapeutic avenue.  
 
Another metabolic disease with comorbidity associated with obesity and metabolic syndrome is 
nonalcoholic fatty liver disease. The incidence ranges from 20 to 30% in the general population 
and up to 75 to 100% in obese individuals. The intestinal microbiota may contribute to the 
development of nonalcoholic fatty liver disease through the complex and cooperative activities 
of two microbe-sensing protein families, namely nucleotide oligomerization domain receptors 
(NLRs) and Toll-like receptors (TLRs) (46, 47), and through inflammasomes (48) that shape 
metabolic events such as lipid accumulation. The loss of NLRP3 and NLRP6 inflammasomes in 
mice is associated with intestinal dysbiosis and results in abnormal accumulation of bacterial 
products such as LPS and bacterial DNA in the hepatic portal circulation. These bacterial 
products stimulate TLR4 and TLR9, respectively, leading to enhanced liver expression of the 
pro-inflammatory cytokine tumor-necrosis factor (TNF)–α, which in turn drives progression of 
nonalcoholic steatohepatitis, a severe form of fatty liver disease. Prebiotics and other dietary 
interventions have been shown to affect the expression of TLR-encoding genes (49), further 
underscoring the importance of the tripartite relationship between the host, microbiota, and 
nutrition.  
 
A key issue is to identify how factors produced by bacteria interact with the host. An oral origin 
of some bacterial components has been proposed, given that peridontal disease has been linked 
to atherosclerosis and hence cardiovascular disease. For example, atherosclerotic plaques contain 
more Proteobacteria species and fewer Firmicutes, and a correlation was found between the 
combined abundance of Veillonella and Streptococcus in the oral cavity and atherosclerotic 
plaque formation (50). Furthermore, changes in diet can result in loosening of the tight junctions 
between gut epithelial cells, which may result in the accumulation of bacterial components in the 
hepatic portal vein with downstream effects on inflammation (51). A chronic high-fat diet 
increases plasma LPS concentrations two- to threefold, a threshold that could be defined as 
metabolic endotoxemia (43, 51). In mice, continuous subcutaneous infusion of LPS induced 
characteristics of metabolic disease such as infiltration of F4/80-positive cells (macrophage-like 
Kupffer cells) and an increase in liver triglyceride content because of CD14, TLR4, NOD1, and 
Myd88-dependent mechanisms (52). This process of LPS-induced activation of TLR4 and other 
receptors suggests an important link between the intestinal microbiota, its rapid evolution over 
recent decades resulting from a change in dietary habits, and low-grade inflammation. Lastly, the 
advent of bariatric surgery, the surgical treatment of obesity, further validates the importance of 
the intestinal microbiota on the control of low-grade inflammation, which is associated with 
hepatic steatosis and metabolic disease (53). Bariatric surgery (particularly the Roux-en-Y 
gastric bypass) conducted on both humans and rodent models induces both metabolic alterations 
in energy metabolism and the urinary excretion of gut microbial metabolites such as 4-cresyl 
sulfate, phenylacetate, and choline degradation products (53). Bariatric surgery also induces a 
marked shift in the composition of the gut microbiota from a predominantly Firmicute and 
Bacteroidetes–dominated microbiota toward one where gammaproteobacteria predominate (53, 
54). After surgery, Faecalibacterium prauznitzii has been shown to correlate inversely with 
markers of inflammation such as C-reactive protein and interleukin-6 (55).  
 
CHARACTERIZING METABOLIC INTERACTIONS BETWEEN HOST AND MICROBE 
The gut microbiota act in a concerted manner to achieve metabolic communication with the host, 
and, as Table 1 shows, many different bacterial genera and species are involved in metabolite 
production. Although there is a global understanding of metabolite flow across the microbe-host 
food web, for many reasons, including the difficulty in ulturing anaerobic bacteria, our 
knowledge of which bacterial species synthesize which metabolites is currently limited. Taking a 
specific example, we do not have a comprehensive understanding of which bacteria are involved 
in synthesis of hippurate, a glycine conjugate of benzoic acid. Yet hippurate is the most widely 
detected urinary metabolite of host-microbial origin in humans, dogs, ruminants, and rodents, 
and its urinary concentrations are modulated by diet, stress, disease, and microbial presence or 
activity (56).  
 
There are various methods for establishing biological or statistical links between the microbes 
and the metabolites that they may produce. Next-generation sequencing methods can provide a 
reconstruction of DNA sequences and insight into the capability of organisms to perform 
metabolic functions but are not able to provide a window on the functionality of particular 
bacteria under complex and changing environmental conditions. Another strategy for assigning 
metabolic origin to specific bacteria is to pursue in vitro experiments by using different model 
systems of the gut (ranging from batch to multiple-stage continuous culture), as well as 
individual pure culture experiments. The principal substrates for these in vitro systems are 
dietary residues (carbohydrates, proteins, and amino acids) and indigenous secretions (mucins). 
Although much can be learned from these in vitro systems, they do not represent the full in vivo 
capacity of the intact gut. Metabolic profiling of biofluids (such as urine, plasma, or fecal water) 
that uses high-resolution spectroscopy offers an alternative strategy for characterizing 
metabolites of microbial origin, and the profiles can subsequently be statistically integrated with 
metagenomics data by using multivariate computational modeling. The challenges for future 
research lie in optimizing the computational capacity and frameworks for coanalysis of vast 
quantities of high-density data acquired on disparate analytical platforms with differing 
processing requirements.  
 
THE UNDISCOVERED COUNTRY: UNDERSTANDING FUTURE MICROBIAL IMPACT 
ON HUMAN HEALTH 
There appear to be sustained long-term shifts in activities and composition of the microbiota that 
are linked to changing life-styles. It is thus possible that, in just a few generations, the 
evolutionary relationships between ourselves and our symbionts could change forever. Given 
that our gut microbiota influence human development, susceptibility to disease, and even the 
outcomes of drug treatment, perhaps we should think now about microbiota biobanking for 
future generations facing unknown biological and infectious disease challenges.  
 
In order to leverage information about the gut microbiota effectively to design new therapeutics, 
the following knowledge gaps need to be addressed.  
 
1. We need an improved understanding of the dynamics and impact of maternal microbiota 
transfer and the influence of infant nutrition on development of the gut microbiota in 
early childhood. We also need to elucidate the influence of host genome variations and 
the fetal environment on the future gut microbiota.  
 
2. It will be important to map the impact of early antibiotic use on the developmental 
ecology, function, and resilience of the microbiota during childhood. As the microbiota 
develops over the first few years of life, there may be greater potential for disruption of 
the long-term microbial state than would be encountered in adults.  
 
3. A deeper knowledge is required regarding how variation in the gut microbiota influences 
drug metabolism, drug bioavailability, and drug toxicity with repercussions for patient 
stratification and personalized health care.  
 
4. Strategies should be developed for the in vitro culture of the complete microbiota in order 
to elucidate bacterial species biology and microbial interactions in engineered ecological 
constructs and synthetic ecosystems.  
 
5. Comprehensive top-down systems biology analyses should be applied to the changing 
immunological and metabolic interactions between the host and its gut microbiota to 
elucidate how these changing interactions affect gut, liver, and brain function.  
 
Perhaps the greatest challenges in this research field, apart from pure metagenomic complexity, 
relate to understanding the temporal dynamics of metabolic communication between the host and 
its gut microbiota, not only on the time scale of a human life but also on an evolutionary time 
scale, in relation to global changes in diet and environmental stressors. Alterations to the gut 
microbiota affect human biological fitness at multiple levels that will need to be better 
understood if we are to elucidate the role of the gut microbiota in specific diseases and the best 
ways to manipulate the microbiota therapeutically to garner human health benefits.  
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